Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Generalized pustular psoriasis (GPP) is a rare, chronic, often unpredictable, severe multisystemic autoinflammatory skin disease from which patients can experience flares, episodes of widespread eruptions of painful, sterile pustules often accompanied by systemic symptoms. The impact of GPP flares and underlying GPP severity on the healthcare resource utilization (HCRU) is not well characterized.

Objective: To quantify HCRU among US GPP patients by flare status and underlying severity.

Methods: Outpatient electronic health record (EHR) data (2017-2023) from the OMNY Health platform were linked with claims. Patients were indexed at first EHR GPP diagnosis code and followed for 1 year. GPP flares were identified from a previously developed algorithm. All-cause hospitalizations, emergency department/urgent care (ED/UC), and outpatient visits were summarized by flare status and underlying severity. Pharmacy and total gross charges were described by number of flares.

Results: A total of 335 patients were included. Patients who flared in the follow-up period (n = 205) had more hospitalizations than patients who did not flare (n = 130; 12.2% vs 6.9%; mean: 0.26 vs 0.09). ED/UC visits were similar between groups (22.9% vs 27.7%; mean: 0.54 vs 0.45), while outpatient visits were greater among patients who did not flare (69.8% vs 78.5%; mean: 5.37 vs 6.56). For patients with 0, 1, and ≥2 flares with HCRU, mean pharmacy charges ($19,887, $25,180, and $57,674, respectively) and total gross charges ($29,196, $40,079, and $52,940, respectively) increased monotonically.

Conclusion: GPP patients who flared and had more severe disease had greater HCRU and charges.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760074PMC
http://dx.doi.org/10.1177/24755303251317193DOI Listing

Publication Analysis

Top Keywords

patients flare
12
patients
10
healthcare resource
8
resource utilization
8
generalized pustular
8
pustular psoriasis
8
gpp flares
8
gpp patients
8
flare status
8
status underlying
8

Similar Publications

The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months.

View Article and Find Full Text PDF

Background: Proper identification and management of flare in atopic dermatitis (AD) is complex, especially in patients being treated with biological drug or small molecules. To date, the definition of flare is not agreed upon. Available scores such as the ADCT (AD control tool) are administered retrospectively to the patient and do not cover key aspects such as self-medication with topical steroids.

View Article and Find Full Text PDF

The intricate interplay between cancer and autoimmune diseases (ADs) is rooted in immune dysregulation, where genetic susceptibility, chronic inflammation, epigenetic modifications, and immunosuppressive therapies contribute to tumorigenesis. The dualistic nature of immune activation complicates therapeutic strategies, as immune checkpoint inhibitors and other immune-stimulatory therapies may exacerbate underlying ADs, leading to immune-related adverse events (irAEs), including organ toxicity, dermatologic reactions, and disease flares. Conversely, immunosuppressive treatments aimed at controlling ADs can compromise anti-tumor immunity and reduce the efficacy of cancer therapies.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by complex disturbances in both innate and adaptive immune responses, often leading to multi-organ involvement. One of the key features of SLE pathogenesis is endothelial dysfunction, which contributes to immune cell infiltration and vascular inflammation. In this context, adhesion molecules such as platelet endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) may reflect the degree of endothelial activation.

View Article and Find Full Text PDF

Polyarteritis nodosa (PAN) rarely affects both intracranial and mesenteric arteries. Evidence on optimal timing of revascularisation and the role of interleukin-6 blockade remains limited. A 73-year-old man with longstanding ankylosing spondylitis presented with weight loss and elevated inflammatory markers.

View Article and Find Full Text PDF